7 citations
,
July 2021 in “JAAD case reports” Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
47 citations
,
January 2016 in “Brain Behavior and Immunity” 5α-reduced progestogens may reduce mood issues and brain damage linked to HIV-1 Tat.
August 2019 in “Anais Brasileiros de Dermatologia” September 2023 in “Journal of the American Academy of Dermatology” Recognizing IPPP is crucial to prevent misdiagnosis and unnecessary treatments.
9 citations
,
December 1987 in “European journal of endocrinology” The treatment significantly reduced hair growth and male hormone levels in hirsute women.
June 2020 in “Annals of the Rheumatic Diseases” Patients need better information about the risks of long-term steroid use.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
January 2025 in “Scholars Journal of Medical Case Reports” Quetiapine may cause hair loss.
11 citations
,
January 1997 in “Skin Pharmacology and Physiology” A certain inhibitor can slow down the decrease in DNA creation in mouse hair follicles, which might help with hair growth.
13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” 12 citations
,
January 2013 in “Indian Journal of Dermatology” Monilethrix is a rare genetic hair disorder that's hard to treat.
Flubendazole in a nanoemulsion can potentially treat lung cancer and cryptococcal meningitis effectively and safely.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
51 citations
,
May 2004 in “American journal of ophthalmology” Using topical prostaglandin F2α for glaucoma may cause loss of eyelash or eyebrow pigment.
12 citations
,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
4 citations
,
November 1999 in “PubMed” Monilethrix is a rare hair disorder causing beaded, fragile hair, often improving on its own over time.
59 citations
,
October 1976 in “Acta Neurologica Scandinavica” Sodium valproate reduced seizures in many patients with resistant epilepsy.
14 citations
,
May 2005 in “Steroids” A new method was developed to make finasteride for treating hair loss.
2 citations
,
November 2022 in “Acta crystallographica. Section B, Structural science, crystal engineering and materials./Acta crystallographica. Section B, Structural science, crystal engineering and materials” A new platinum complex was made and studied, which might help fight cancer better.
1 citations
,
October 1997 in “PubMed” Finasteride and flutamide can effectively treat hirsutism, with abdominal hairs showing the most sensitivity to the treatment.
269 citations
,
May 2002 in “Hormones and Behavior” Lowering 3α,5α-THP in the hippocampus increases anxiety and depression in proestrous rats.
September 2024 in “Journal of the American Academy of Dermatology” The patient responded well to treatment with no disease progression.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
11 citations
,
May 2006 in “Journal of the European Academy of Dermatology and Venereology” Combining paroxetine and triamcinolone effectively treats both alopecia areata and depression.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
17 citations
,
September 2013 in “The International Journal of Neuropsychopharmacology”
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
January 2025 in “Journal of Prescribing Practice”